Biomarker Consortium

GI Cancer

Pancreatic Cancer

Expert Sound Bites

Canonical  and Non-Canonical Homologous Recombination Gene Mutations in Pancreatic Cancer

Rare Gene Fusions in Pancreatic Cancer: Recent Updates in Biomarker and Drug Development

BRAF V600E in Pancreatic Cancer: Recent Updates in Biomarker and Drug Development

KRAS in Pancreatic Cancer: Recent Updates in Biomarker and Drug Development

BRCA Positive Pancreatic Cancer: Navigating Treatment Options

Testing for BRCA Mutations in Pancreatic Cancer

The Evolving Role of Liquid biopsy in Pancreatic Cancer

Disparities in Cancer Care

Global Oncology

Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

Oncology Business Management

Precision Medicine in Oncology®

CAR T-cell Therapy

Hepatocellular Carcinoma

Gastric Cancer

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Pediatric Oncology

Sarcomas

Supportive Care

The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT. 

Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL

Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.

Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL

The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL. 

Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL

BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.

BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

OncLive App

Interactive Tools

Subscribe

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Articles

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

The OncLive Insider app is live!

CME Opportunities

Specialty

Additional Resources

No One Missed Provider Campaign

Adopting Consensus Terms for Testing in Precision Medicine

Fostering a High-Functioning Team in Cancer Care Using the 4R Oncology Model

Molecular in My Pocket Reference Card Series

Recent Updates in Molecular Targets and Pathways in Lung Cancer

Uncommon Mutations in NSCLC

Biomarkers in NSCLC

Test your Biomarkers

Molecular in My Pocket Referenced Card Series – Colorectal Cancer

Stomach Cancer Biomarkers

Biomarkers in Gastrointestinal Cancers

The Clinical Impact of Testing for Biomarkers in Gastric Cancer Patients: A Real-World Cohort

Best Practices Along the Tissue Journey in NSCLC

Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non–Small Cell Lung Cancer

Improving Biomarker Testing and Applying Testing Results in Clinical Practice

Health Equity

Biomarker Testing in Patients With Non–Small Cell Lung Cancer

Eliminating Precision Medicine Disparities

Ferrying Oncologists Across the Chasm of Interpreting Biomarker Testing Reports: Systematic Support Needed to Improve Care and Decrease Disparities

Additional Resources

Biomarkers in NSCLC

Biomarkers in Gastrointestinal Cancers

Improving Biomarker Testing and Applying Testing Results in Clinical Practice

Addressing Barriers to Access and Improving Equity in Biomarker Testing

Websites